Form D · Biotechnology
AdvanCell, Inc.
Cambridge, MA · CIK 0002144758
Offering snapshot reported Jul 16, 2026 · SEC filing
- Reported sold
- $218M Offering amount: $315M
- Investors reported
- 41 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 16, 2026 | Initial | $218,333,294 | No comparison | 41 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-591090
Source: Form D, filed Jul 16, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andrew Adamovich | Director |
| Anthony Aiudi | Director |
| Jamil Beg | Director |
| Kevin Cameron | Director |
| Nik Economopoulos | Director |
| Christopher Gagliardi | Director |
| Andrew Kay | Director |
| Wing Cheong Lam | Director |
| Philina Lee | Director, Executive |
| Bali Muralidhar | Director |
| Aaron Pickett | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
245 Main Street
Cambridge, MA, 02142
Phone: +64 22 799 1300
Cambridge, MA, 02142
Phone: +64 22 799 1300